Drug intelligence / Profile preview

MM018

Development stage: Preclinical
Lead developer: Mucommune
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MM018 is an investigational mucosal antibody being developed by Mucommune. Currently in the discovery phase, the asset is part of Mucommune's portfolio of engineered antibodies designed to function effectively within the mucus layer to trap and neutralize pathogens or other targets at mucosal surfaces. The specific biological target and the primary disease indication for MM018 have not yet been disclosed by the developer.

Beyond the preview

Go deeper on MM018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MM018.

Explore the full profile